Opus Genetics, Inc. financial data

Symbol
IRD on Nasdaq
Industry
Pharmaceutical Preparations
Location
8 Davis Drive, Suite 220, Durham, NC
State of incorporation
DE
Fiscal year end
December 31
Former names
Ocuphire Pharma, Inc. (to 10/22/2024), REXAHN PHARMACEUTICALS, INC. (to 11/9/2020), CORPORATE ROAD SHOW DOT COM INC (to 4/29/2005), FERRARO FRANK (to 4/29/2003)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 635 % -42.4%
Debt-to-equity 21.4 % +115%
Return On Equity -180 % -708%
Return On Assets -132 % -553%
Operating Margin -565 % -918%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 45.5M shares +83.3%
Common Stock, Shares, Outstanding 31.6M shares +31.7%
Entity Public Float 38.7M USD -56.6%
Common Stock, Value, Issued 3K USD +50%
Weighted Average Number of Shares Outstanding, Basic 26.7M shares +23.7%
Weighted Average Number of Shares Outstanding, Diluted 26.7M shares +23.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 11M USD -42.3%
General and Administrative Expense 18.2M USD +52.3%
Operating Income (Loss) -62.1M USD -488%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -57.5M USD -477%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -57.5M USD -476%
Earnings Per Share, Basic -2.15 USD/shares -367%
Earnings Per Share, Diluted -2.15 USD/shares -367%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 30.3M USD -40%
Accounts Receivable, after Allowance for Credit Loss, Current 3.56M USD +285%
Other Assets, Current 86K USD +68.6%
Assets, Current 36.6M USD -32.1%
Property, Plant and Equipment, Net 252K USD
Assets 36.9M USD -31.7%
Accounts Payable, Current 3.15M USD +46.2%
Employee-related Liabilities, Current 1.48M USD +96.7%
Accrued Liabilities, Current 8.15M USD +349%
Liabilities, Current 11.3M USD +179%
Liabilities 11.3M USD +179%
Retained Earnings (Accumulated Deficit) -139M USD -70.6%
Stockholders' Equity Attributable to Parent 6.72M USD -86.5%
Liabilities and Equity 36.9M USD -31.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.72M USD -56.8%
Net Cash Provided by (Used in) Financing Activities 2.38M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 125M shares +66.7%
Common Stock, Shares, Issued 31.6M shares +31.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 30.3M USD -40%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 35.4M USD +75.8%
Deferred Tax Assets, Gross 35.4M USD +75.9%
Depreciation 10K USD +66.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -57.5M USD -476%
Property, Plant and Equipment, Gross 25K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 20.3M USD +59.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 9.99M shares -0.14%
Additional Paid in Capital 146M USD +10.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 27K USD
Share-based Payment Arrangement, Expense 3.36M USD -4.22%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%